The price of INmune Bio Inc (NASDAQ:INMB) shares last traded on Wall Street fell -15.13% to $5.33.
INMB stock price is now -28.18% away from the 50-day moving average and -20.70% away from the 200-day moving average. The market capitalization of the company currently stands at $123.71M.
With the price target of $23, Rodman & Renshaw recently initiated with Buy rating for INmune Bio Inc (NASDAQ: INMB). On October 21, 2024, Alliance Global Partners recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Raymond James’ rates the stock as ‘Outperform’
In other news, Moss David J, Chief Financial Officer bought 10,000 shares of the company’s stock on Sep 30 ’24. The stock was bought for $52,868 at an average price of $5.29. Upon completion of the transaction, the Chief Financial Officer now directly owns 1,285,869 shares in the company, valued at $6.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12 ’24, President and CEO Tesi Raymond Joseph bought 15,380 shares of the business’s stock. A total of $98,048 was incurred on buying the stock at an average price of $6.38. This leaves the insider owning 1,554,106 shares of the company worth $8.28 million. A total of 28.90% of the company’s stock is owned by insiders.
During the past 12 months, INmune Bio Inc has had a low of $4.32 and a high of $10.50. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 2.64, and a quick ratio of 2.64. The fifty day moving average price for INMB is $7.421 and a two-hundred day moving average price translates $6.72115 for the stock.
The latest earnings results from INmune Bio Inc (NASDAQ: INMB) was released for 2025-03-31. The net profit margin was -81592.00% and return on equity was -139.01% for INMB. The company reported revenue of $50000.0 for the quarter, compared to $14000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 257.14 percent.
